BerGenBio Partners with Tempus to Enhance NSCLC Clinical Trial with AI-Driven Data Insights

In order to progress the clinical development of its selective AXL inhibitor bemcentinib in first-line (1L) Non-Small Cell Lung Cancer (NSCLC) patients with STK11 mutations, biopharmaceutical startup BerGenBio has teamed up with Tempus, a preeminent AI technology company. The purpose of the present BGBC016 Phase 1b/2a trial is to evaluate the advantages of supplementing the standard of care medication for 1L STK11m patients with bemcentinib. Through the partnership, BerGenBio will be able to access a customised cohort of real-world clinical and molecular data from Tempus, creating a synthetic control for the research.

With the use of Tempus' AI-enabled platform, BerGenBio will be able to obtain personalised analyses of Tempus data, offering more profound understanding of the genetic profile and treatment outcomes of NSCLC patients with STK11m. As the next stage in the development of bemcentinib, the firms intend to submit insights obtained from the collected data to regulatory regulators following the completion of the BGBC016 research. Martin Olin, CEO of BerGenBio, expressed enthusiasm about the company's collaboration with Tempus to improve knowledge of the biology of disease and the results of treatment, which would ultimately lead to the development of bemcentinib.